Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of BGM0504 Injection in Overweight/Obese Participants
NCT07382908Phase 1Completed
- Sponsor
- BrightGene Bio-Medical Technology
- Start
- Dec 2025
- Primary completion
- Apr 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of BGM0504 in obesity (3 arms), sponsored by BrightGene Bio-Medical Technology. Primary endpoints: Peak Plasma Concentration and Area under the plasma concentration versus time curve. Started Dec 2025; status: completed.
02
Drugs
BGM0504
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07382908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07382908.